Latest News on ANGO

Financial News Based On Company


Advertisement
Advertisement

Reasons to Hold AngioDynamics Stock in Your Portfolio for Now

https://www.tradingview.com/news/zacks:7f3dc2fcc094b:0-reasons-to-hold-angiodynamics-stock-in-your-portfolio-for-now/
AngioDynamics (ANGO) is recommended as a stock to hold due to strong performance in its first quarter of fiscal 2027, driven by its NanoKnife technology and a broad product line in the Med Tech sector. The company has surpassed Zacks Consensus Estimates in earnings for four consecutive quarters, showing continued growth in key areas like peripheral vascular disease and oncology markets. Despite concerns about tariffs and inflation, AngioDynamics' strategic shift towards higher-growth Med Tech products and positive adjusted EBITDA contribute to a favorable outlook.

AngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://sg.finance.yahoo.com/news/angiodynamics-announces-inducement-grants-under-230000049.html
AngioDynamics, Inc. announced inducement grants to Eric Honroth in connection with his appointment as Chief Executive Officer, effective November 2, 2026. These awards include time-based and performance-based restricted stock units, granted under Nasdaq Listing Rule 5635(c)(4) and approved by the independent Compensation Committee. The awards will vest over specified periods, subject to Mr. Honroth's continued service and the achievement of performance metrics for the performance-based units.

AngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://www.quantisnow.com/insight/angiodynamics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6779637
AngioDynamics announced inducement grants of restricted stock units (RSUs) to its new Chief Executive Officer, Eric Honroth, effective November 2, 2026. The awards consist of three RSU grants totaling 62,928, 62,928, and 38,265 shares, with a portion tied to performance targets. These grants are intended to incentivize Honroth to join the company but could lead to future share dilution for existing shareholders.

ANGO: SEC Form 3 filed by AngioDynamics Inc.

https://www.quantisnow.com/insight/sec-form-3-filed-by-angiodynamics-inc-6773799
Quantisnow reported an SEC Form 3 filing by AngioDynamics Inc. (ANGO) on November 4, 2026. The report includes historical stock performance data for ANGO following previous headlines, noting a median move of 1.9% in either direction across 24 sessions. It also provides market data and other recent news about AngioDynamics.

ANGIODYNAMICS INC Initial Statement of Beneficial Ownership

https://www.stocktitan.net/sec-filings/ANGO/form-3-angiodynamics-inc-initial-statement-of-beneficial-ownership-891f06c52f46.html
This article details the initial statement of beneficial ownership (Form 3) filed by Eric Honroth, the President and CEO of AngioDynamics Inc. The filing, dated November 4, 2026, indicates that Honroth does not beneficially own any securities of the company at this time. The document provides standard SEC Form 3 details, including the reporting person's address and relationship to the issuer.
Advertisement

AngioDynamics (ANGO) CEO also receives 38,265 stock units replacing forfeited prior-employer equity.

https://www.stocktitan.net/sec-filings/ANGO/form-4-angiodynamics-inc-insider-trading-activity-dccb95c34bc9.html
AngioDynamics (ANGO) President and CEO Eric Honroth received a total of 101,193 restricted stock units and 62,928 performance rights on November 2, 2026. This includes 38,265 replacement restricted stock units to compensate for equity forfeited from his previous employer. The awards have various vesting schedules and performance conditions tied to the company's revenue, adjusted EBITDA, and relative total shareholder return.

Have Insiders Sold AngioDynamics Shares Recently?

https://simplywall.st/stocks/us/healthcare/nasdaq-ango/angiodynamics/news/have-insiders-sold-angiodynamics-shares-recently
AngioDynamics insiders have recently sold shares, with the Executive VP & CFO selling US$311k worth of stock and the Senior Vice President of Regulatory Affairs selling US$344k. Despite these sales, some at prices above the current stock value, there have been no insider purchases in the last year, leading to a cautious outlook on the company's stock. Insider ownership remains at 9.7%, suggesting some alignment with shareholders.

AngioDynamics Inc (UG2.DU) Seasonal returns chart

https://au.finance.yahoo.com/quote/UG2.DU/seasonality/
This article from Yahoo Finance presents a seasonal returns chart for AngioDynamics Inc (UG2.DU), showing the average monthly price return for the years 2025-2026. It includes current stock information, indicating the stock closed at 10.80 EUR, down 0.92%.

AngioDynamics (ANGO) Stock Price, Chart & Analysis

https://www.debelegger.nl/en/stock/ANGO.US
This article provides a comprehensive analysis of AngioDynamics (ANGO) stock, detailing its current price, market capitalization, and key financial figures. It assesses the company's quality, valuation, and growth prospects using various metrics and offers a "Belegger score" based on methods by Buffett and Lynch, concluding with hypothetical future price scenarios and analyst ratings.

AngioDynamics | 4: Statement of changes in beneficial ownership of securities-Officer Trowbridge Stephen A

https://www.moomoo.com/news/notice/1003053886/statement-of-changes-in-beneficial-ownership-of-securities-officer-trowbridge
This document is a statement of changes in beneficial ownership of securities for AngioDynamics, specifically related to Officer Stephen A. Trowbridge. It is a Form 4 filing, indicating a transaction or change in his holdings.
Advertisement

CFO Stephen A. Trowbridge sells 25,335 AngioDynamics (ANGO) shares across two October sales.

https://www.stocktitan.net/sec-filings/ANGO/form-4-angiodynamics-inc-insider-trading-activity-579b385b5e80.html
AngioDynamics Inc.'s EVP and CFO, Stephen A. Trowbridge, sold a total of 25,335 shares of Common Stock in two separate transactions in October 2026. The sales occurred on October 28 and October 29, with weighted-average prices of $12.17 and $12.27 per share, respectively. These transactions were reported in an SEC Form 4 filing and reduced his direct holdings to 280,461 shares.

An officer plans to sell 23,615 shares of AngioDynamics (Nasdaq: ANGO).

https://www.stocktitan.net/sec-filings/ANGO/144-angiodynamics-inc-sec-filing-2501fbcfe4f7.html
Stephen Trowbridge, an officer at AngioDynamics, Inc., plans to sell 23,615 common shares with an aggregate market value of $289,722 around October 29, 2026. These shares were acquired through restricted stock, an Employee Stock Purchase Plan, and as performance shares. A separate prior-sales entry also recorded the sale of 1,720 common shares on October 28, 2026, for $20,929.09.

Port Catheter Lawsuit Claims Defective Design Led to Fungal Bloodstream Infection

https://www.aboutlawsuits.com/angiodynamics-port-catheter-lawsuit/smartport-lawsuit-alleges-smartport-caused-severe-fungal-bloodstream-infection/
A Texas woman has filed a product liability lawsuit against AngioDynamics Inc. and Navilyst Medical Inc., alleging that a defective SmartPort port catheter caused her to develop a candida fungal bloodstream infection. The lawsuit claims the companies manufactured and marketed implants with inferior materials, leading to the device fracturing and causing severe health issues, including a 16-day hospitalization for sepsis and other complications. This case is part of a growing number of port catheter lawsuits, with similar federal claims consolidated in multidistrict litigations.

One of AngioDynamics’ two November conference appearances will be webcast live.

https://www.stocktitan.net/news/ANGO/angio-dynamics-to-participate-in-upcoming-investor-r0lwj13jqi4z.html
AngioDynamics (NASDAQ: ANGO) announced its participation in two investor conferences in November 2026: the UBS Global Healthcare Conference and Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum. A live webcast will be available for the Canaccord Genuity presentation through the company's website. The company specializes in medical technology for vascular systems and cancer treatment.

AngioDynamics, Inc. Estimates – NASDAQ:ANGO

https://www.tradingview.com/symbols/NASDAQ-ANGO/financials-estimates/
This page on TradingView provides financial estimates and actuals for AngioDynamics, Inc. (NASDAQ: ANGO). Users can explore reported financial data, analyst estimates across various statements, and visualize trends over time. The platform offers comparisons between actual results and average, high, and low estimates for the medical specialties company.
Advertisement

AngioDynamics study shows survival benefit for pancreatic cancer

https://www.investing.com/news/company-news/angiodynamics-study-shows-survival-benefit-for-pancreatic-cancer-93CH-4963035
AngioDynamics Inc. announced positive results from its DIRECT study, showing that its NanoKnife System, used in conjunction with standard-of-care systemic therapy, significantly extended median overall survival for Stage III pancreatic cancer patients to 28 months, compared to 15 months for those receiving standard therapy alone. The company also secured a new Category I CPT code for irreversible electroporation in pancreatic tumor ablation, effective January 1, 2027, which standardizes reporting for the procedure. While the study was non-randomized, the findings suggest a strong association with improved survival, though AngioDynamics' primary commercial focus for NanoKnife remains prostate cancer.

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

https://www.stocktitan.net/news/ANGO/angio-dynamics-announces-publication-of-direct-study-results-and-new-7lzzscgkx03u.html
AngioDynamics announced the publication of results from its DIRECT study in The Oncologist, which found that an irreversible electroporation (IRE)-based treatment strategy was associated with longer overall survival in Stage III pancreatic cancer patients. Concurrently, the company announced a new Category I CPT code for open IRE ablation of pancreatic tumors, set to take effect on January 1, 2027. This code will provide a standardized mechanism for reporting these procedures, further advancing the coding infrastructure for IRE treatments.

Chemo Port Fracture Lawsuit Alleges SmartPort Problems Led to Removal Surgery

https://www.aboutlawsuits.com/angiodynamics-port-catheter-lawsuit/chemo-port-fracture-lawsuit-smartport-problems-removal-surgery/
A South Carolina woman has filed a product liability lawsuit against AngioDynamics Inc. and Navilyst Medical Inc., alleging that a defective SmartPort catheter fractured inside her late husband, necessitating additional surgery for its removal. The lawsuit claims that improper concentrations and mixing of barium sulfate weakened the catheter, leading to the fracture and causing physical and emotional suffering, as well as financial losses. This case joins hundreds of other AngioDynamics port catheter lawsuits centralized in California, alongside a separate multidistrict litigation involving Bard PowerPort devices.

Humana applies Medicare coverage rules to a non-heat treatment for some prostate and liver cancer patients.

https://www.stocktitan.net/news/ANGO/angio-dynamics-announces-humana-medicare-advantage-coverage-policy-4t7v7iw5b168.html
Humana has updated its Medicare Advantage policy to cover AngioDynamics' NanoKnife System for eligible patients with intermediate-risk prostate cancer and certain liver tumors, effective October 1, 2026. This decision applies Local Coverage Determination (LCD) L40205 medical necessity criteria, supporting broader and more consistent access to the non-thermal irreversible electroporation (IRE) treatment. The policy follows previous milestones like the issuance of Category I CPT codes for prostate and liver tissue ablation.

AngioDynamics Q1 revenue rises 6.9%, but shares drop 21% despite positive results and CEO change.

https://pluang.com/en/news-feed/angiodynamics-hasil-q1-fy2027-dan-target-harga-18
AngioDynamics reported a 6.9% increase in Q1 fiscal 2027 revenue to $80.9 million and a narrowed adjusted loss, yet its shares dropped over 21%. The company also announced Eric Honroth as the new President and CEO. H.C. Wainwright maintained a Buy rating but lowered its price target for AngioDynamics.
Advertisement

HC Wainwright & Co. maintains Buy rating on AngioDynamics, $18 price target

https://www.tradingview.com/news/tradingview:53d48ecbc2ffe:0-hc-wainwright-co-maintains-buy-rating-on-angiodynamics-18-price-target/
HC Wainwright & Co. has reiterated its Buy rating for AngioDynamics (ANGO), setting an $18 price target, which suggests a 57.9% upside from its recent closing price. The firm's positive outlook is based on AngioDynamics' strong revenue growth of 6.9% year-over-year in fiscal 1Q27, particularly a 13.2% increase in MedTech sales, and the company's maintained FY2027 guidance projecting $336–341 million in net sales and a return to positive operating cash flow.

AngioDynamics Q1 Earnings Call Highlights

https://es.tradingview.com/news/marketbeat:9a28035d4094b:0-angiodynamics-q1-earnings-call-highlights/
AngioDynamics reported a 6.9% increase in Q1 fiscal 2027 revenue, reaching $80.9 million, driven by strong growth in its Med Tech segment. The company maintained its full-year outlook and announced Eric Honroth as the new president and CEO, effective November 2. Med Tech revenue, particularly from Auryon and NanoKnife platforms, saw significant expansion, contributing to a narrowing GAAP net loss and improved gross margin.

Teleconferência de Resultados do 1º Trimestre Fiscal de 2027 da AngioDynamics (ANGO): Receita de MedTech Cresce 13,2%

https://www.tradingkey.com/pt/news/transcripts/262207004-TradingKey
AngioDynamics reported a 6.9% increase in Q1 FY2027 revenue to $80.9 million, driven by a 13.2% rise in its Med Tech segment. Key growth drivers included the Auryon and NanoKnife platforms, with record prostate procedure volumes for NanoKnife. The company maintained its full-year guidance and announced a leadership transition, with Eric Honroth succeeding James Clemmer as President and CEO.

ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y

https://es.tradingview.com/news/zacks:38e37c6a9094b:0-ango-q1-earnings-beat-estimates-on-med-tech-growth-revenues-up-y-y/
AngioDynamics (ANGO) reported a narrower-than-expected loss per share and an increase in revenues for Q1 fiscal 2027, driven primarily by strong performance in its Med Tech segment. The company's Med Tech products, including Auryon, AlphaVac, and NanoKnife, showed significant growth, contributing to an expanded gross margin. Despite a decline in stock value post-earnings, AngioDynamics reiterated its fiscal 2027 revenue guidance and highlighted strategic clinical advancements and a leadership transition aimed at further Med Tech growth.

Port Catheter Lawsuit Filed After Infection Led to Sepsis, Death

https://www.aboutlawsuits.com/angiodynamics-port-catheter-lawsuit/port-catheter-lawsuit-infection-sepsis-death/
An Oklahoma woman has filed a lawsuit against AngioDynamics Inc. and Navilyst Medical Inc., alleging that her husband's death from sepsis was caused by a defective SmartPort port catheter. The complaint claims the manufacturers were aware of design flaws but failed to warn patients and medical professionals. This case joins hundreds of similar lawsuits consolidated in an MDL, with plaintiffs arguing that the port catheters' materials can deteriorate and lead to serious infections.
Advertisement

With its CEO set to retire, AngioDynamics (ANGO) names a Getinge executive as successor.

https://www.stocktitan.net/sec-filings/ANGO/8-k-angiodynamics-inc-reports-material-event-691fe88756aa.html
AngioDynamics has appointed Eric Honroth as its new President and Chief Executive Officer, effective November 2, 2026, succeeding James C. Clemmer who is retiring. Honroth, formerly of Getinge AB, will receive an annual base salary of $735,000, a target annual bonus of 95% of his salary, and significant long-term incentive awards, alongside various allowances. Clemmer will continue in a consulting role for up to a year to ensure a smooth transition.

Sales rose 6.9% at AngioDynamics (ANGO), while its quarterly net loss narrowed.

https://www.stocktitan.net/sec-filings/ANGO/8-k-angiodynamics-inc-reports-material-event-7ac8d41acfb3.html
AngioDynamics (ANGO) reported a narrowed net loss of $7.1 million in Q1 FY2027, compared to $10.9 million in the prior-year quarter, with net sales increasing by 6.9% to $80.9 million. Med Tech sales grew 13.2% to $39.9 million, driven by strong performance in Auryon, Mechanical Thrombectomy, and NanoKnife platforms. The company reiterated its fiscal 2027 guidance and announced Eric Honroth as the new President and CEO, effective November 2, 2026.

AngioDynamics stock slips 4% despite beating estimates on Med Tech growth

https://finance.yahoo.com/markets/stocks/articles/angiodynamics-stock-slips-4-despite-105144592.html
AngioDynamics Inc. (NASDAQ: ANGO) reported better-than-expected Q1 fiscal 2027 results, with adjusted loss per share of -$0.04 and revenue of $80.9 million, driven by strong Med Tech segment growth. Despite this performance, the company's stock slid 4.26% in pre-market trading. The company also announced Eric Honroth will succeed Jim Clemmer as President and CEO effective November 2, 2026.

AngioDynamics Stock Is Falling Thursday: What's Going On?

https://www.benzinga.com/markets/earnings/26/10/62255996/angiodynamics-stock-is-falling-thursday-whats-going-on
AngioDynamics Inc. (NASDAQ: ANGO) saw its stock plunge over 21% despite reporting better-than-expected first-quarter financial results. The company beat consensus estimates for adjusted loss per share and revenue, with strong growth in Med Tech and NanoKnife sales, though AngioVac sales declined year-over-year. AngioDynamics also announced a new President and CEO and received FDA approval for a feasibility study for its NanoKnife technology.

AngioDynamics, Inc. 2027 Q1 - Results - Earnings Call Presentation (NASDAQ:ANGO) 2026-10-08

https://seekingalpha.com/article/4952885-angiodynamics-inc-2027-q1-results-earnings-call-presentation
AngioDynamics, Inc. (NASDAQ: ANGO) has released its Q1 2027 earnings call presentation. The company reported an EPS of -$0.04, beating estimates by $0.07, and revenue of $80.92M, a 6.87% year-over-year increase, beating estimates by $415.00K. This presentation provides details discussed during their recent earnings call.
Advertisement

Sales rose 6.9% at AngioDynamics (ANGO), but the quarter still ended in a loss.

https://www.stocktitan.net/sec-filings/ANGO/10-q-angiodynamics-inc-quarterly-earnings-report-344f778dfcf1.html
AngioDynamics (ANGO) reported a Q1 net loss of $7.1 million, a narrower loss compared to $10.9 million in the prior year, despite a 6.9% increase in net sales to $80.9 million. This sales growth was driven by a 13.2% rise in Med Tech sales and a 1.4% increase in Med Device sales. The company also announced the appointment of Eric Honroth as President and CEO, effective November 2, 2026.

A Nov. 17 vote at AngioDynamics (ANGO) would raise its equity plan reserve to 10,050,000 shares.

https://www.stocktitan.net/sec-filings/ANGO/def-14a-angiodynamics-inc-definitive-proxy-statement-ac3064c3d5e1.html
AngioDynamics (ANGO) is asking shareholders to approve an amendment to its 2020 Equity Incentive Plan, increasing the shares reserved from 9,050,000 to 10,050,000. This proposal is part of the company's annual meeting on November 17, 2026, where shareholders will also vote on director elections, auditor ratification, and executive compensation. The Board recommends voting "FOR" all proposals, citing the need for competitive equity incentives to attract and retain talent.

AngioDynamics Shares Fall 4.3% Despite Q1 Earnings Beat and Strong Med Tech Growth

https://finance.yahoo.com/healthcare/articles/angiodynamics-shares-fall-4-3-121942933.html
AngioDynamics (NASDAQ: ANGO) reported strong first-quarter fiscal 2027 results, exceeding analyst expectations with an adjusted loss of $0.04 per share and revenue of $80.9 million, driven by a 13.2% increase in its Med Tech segment. Despite the positive financial performance and reaffirmed full-year guidance, the company's shares fell 4.3% in pre-market trading. The report also announced a leadership transition, with Eric Honroth set to succeed Jim Clemmer as CEO in November 2026.

AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer

https://finance.yahoo.com/healthcare/articles/angiodynamics-announces-appointment-eric-honroth-100000982.html
AngioDynamics, Inc. (NASDAQ: ANGO) has appointed Eric Honroth as its new President and Chief Executive Officer, effective November 2, 2026. Honroth brings over 20 years of medical technology leadership experience and will succeed Jim Clemmer, who is retiring after a decade in the role. The appointment aims to build on AngioDynamics' momentum, drive revenue growth, and expand margins.

AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence

https://finance.yahoo.com/healthcare/articles/angiodynamics-pert-consortium-name-jacobi-100000381.html
AngioDynamics and The PERT Consortium® have selected Jacobi Hospital as a recipient of the ALPHA-PE Research Fund award. This funding supports an independent, investigator-led study by Dr. Jonathan Alis and Dr. Seth I. Sokol to evaluate CT pulmonary angiography radiomics as predictors of thrombus biology, thrombectomy success, and long-term outcomes in pulmonary embolism patients. The research aims to generate real-world evidence to help physicians make more informed treatment decisions and personalize care for PE patients.
Advertisement

A Bronx hospital won a research award to test if scans can predict clot-removal success.

https://www.stocktitan.net/news/ANGO/angio-dynamics-and-the-pert-consortium-name-jacobi-hospital-as-alpha-zmnjj18lugzm.html
AngioDynamics and The PERT Consortium have awarded Jacobi Hospital investigators with an ALPHA-PE Research Fund grant. The study, led by Dr. Jonathan Alis and Dr. Seth I. Sokol, will examine CT pulmonary angiography radiomics to predict the success of thrombectomy and long-term outcomes for pulmonary embolism patients. This research aims to provide crucial real-world evidence to help physicians make more informed and individualized treatment decisions for PE patients.

Sales reached $320.2 million at AngioDynamics (ANGO). Five executives received cash bonuses.

https://www.stocktitan.net/sec-filings/ANGO/10-k-a-angiodynamics-inc-amends-annual-report-71d34edcd2ba.html
AngioDynamics reported net sales of $320.2 million for fiscal year 2026, exceeding its $312 million target. As a result, all five named executive officers received annual cash incentive payouts equal to 180% of their target bonuses. The company's CEO, James C. Clemmer, announced his intention to retire by November 30, 2026, or upon the appointment of a successor, and the company has retention agreements in place for other key executives.

A successor's appointment could set the CEO's retirement date at AngioDynamics (ANGO). There's another trigger.

https://www.stocktitan.net/sec-filings/ANGO/10-k-a-angiodynamics-inc-amends-annual-report-74f7c2c6c067.html
AngioDynamics CEO James C. Clemmer announced his intention to retire by November 30, 2026, or upon the appointment of a successor, with the possibility of monthly extensions by mutual agreement. The company recently amended its fiscal 2026 annual report to include updated XBRL tagging and disclosed performance against cash-incentive targets, showing net sales of $320.2 million against a $312 million target and adjusted EBITDA of $18.2 million versus a $10.5 million target. Executive compensation for fiscal 2026 was largely performance-based, with cash incentive payouts at 180% of target for named executive officers.

AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026

https://finance.yahoo.com/healthcare/articles/angiodynamics-report-fiscal-2027-first-203000231.html
AngioDynamics, Inc. (NASDAQ: ANGO) announced it will release its financial results for the first quarter of fiscal year 2027 before market open on Thursday, October 8, 2026. The company will also host a conference call at 8:00 AM ET on the same day to discuss these results. Investors can access the webcast and replay through the company's website.

AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026

https://au.finance.yahoo.com/news/angiodynamics-report-fiscal-2027-first-203000231.html
AngioDynamics, Inc. (NASDAQ: ANGO) announced it will report its fiscal year 2027 first quarter financial results before market open on Thursday, October 8, 2026. The company's management will host a conference call at 8:00 am ET on the same day to discuss the results, which will also be webcast. A replay of the call will be available until October 15, 2026.
Advertisement

AngioDynamics Xcela Port Lawsuit Alleges Infection, Migration Caused by Defective Catheter

https://www.aboutlawsuits.com/angiodynamics-port-catheter-lawsuit/angiodynamics-xcela-port-lawsuit-infection-migration-defective-catheter-design/
A Delaware woman has filed a product liability lawsuit against AngioDynamics, claiming her Xcela port catheter was defectively designed, migrated, and caused infection. The lawsuit alleges that AngioDynamics failed to warn about the risks of migration, fractures, and infections associated with their port catheters. This case joins hundreds of similar AngioDynamics port catheter lawsuits consolidated in federal court, alleging defective designs and inadequate warnings.

387,188 Shares in AngioDynamics, Inc. $ANGO Bought by Western Standard LLC

https://www.marketbeat.com/instant-alerts/filing-387188-shares-in-angiodynamics-inc-ango-bought-by-western-standard-llc-2026-08-20/
Western Standard LLC has acquired 387,188 shares of AngioDynamics, Inc. (NASDAQ:ANGO) for approximately $5.04 million, making it their 17th largest position. AngioDynamics recently beat quarterly earnings expectations, reporting a loss of $0.07 per share on $86.61 million in revenue, exceeding estimates despite remaining unprofitable. Analyst sentiment is mixed, with a consensus "Hold" rating and a price target of $19.50.

AngioDynamics (NASDAQ:ANGO) Reaches New 12-Month High - Still a Buy?

https://www.marketbeat.com/instant-alerts/angiodynamics-nasdaqango-reaches-new-12-month-high-still-a-buy-2026-08-19/
AngioDynamics (NASDAQ:ANGO) has reached a new 52-week high of $16.25, with mixed analyst ratings including "buy" and "strong sell." Despite beating quarterly earnings and revenue estimates, the company remains unprofitable, and an insider recently sold shares. The consensus rating for ANGO is "Hold" with a $19.50 price target.

Angiodynamics, Inc. (UG2) Q3 2023 Earnings Report - Results, Call & Slides

https://www.tipranks.com/stocks/de:ug2/earnings/q3-2023-report
Angiodynamics, Inc. (UG2) reported its Q3 2023 earnings, missing both EPS and revenue expectations. The company posted an actual EPS of -€0.03 against a consensus of >-€0.01, and actual revenue of €69.95M compared to an expected €72.11M, though revenue did show a 9.11% year-over-year growth. An earnings call was held on March 30, 2023, and the next earnings report is estimated for October 1, 2026.

Angiodynamics, Inc. (UG2) Q1 2025 Earnings Report - Results, Call & Slides

https://www.tipranks.com/stocks/de:ug2/earnings/q1-2025-report?hash=slideDeck
Angiodynamics, Inc. (UG2) released its Q1 2025 earnings report, showing an actual EPS of -€0.10, beating the consensus of -€0.13 by +€0.03. However, the company missed revenue expectations, reporting €58.49M against an expected €58.88M, marking a -14.22% year-over-year decline. The earnings call took place on October 3, 2024, and the next earnings date is estimated for October 1, 2026.
Advertisement

AngioDynamics at Canaccord Genuity conference: growth pivot deepens

https://www.investing.com/news/transcripts/angiodynamics-at-canaccord-genuity-conference-growth-pivot-deepens-93CH-4852599
AngioDynamics discussed its strategic pivot from a legacy catheter business to a high-growth MedTech portfolio at the Canaccord Genuity conference. The company highlighted 18% MedTech revenue growth in fiscal 2026, now comprising 47% of total revenue, and projected 12-15% MedTech growth for fiscal 2027. Key growth drivers include Auryon, mechanical thrombectomy, and NanoKnife, with an ongoing search for a new CEO as Jim Clemmer plans to retire by year-end 2026.

AngioDynamics, Inc. (ANGO) Presents at Canaccord Genuity's 46th Annual Growth Conference - Slideshow

https://seekingalpha.com/article/4934976-angiodynamics-inc-ango-presents-at-canaccord-genuitys-46th-annual-growth-conference-slideshow
AngioDynamics, Inc. (ANGO) presented a slideshow at Canaccord Genuity's 46th Annual Growth Conference. The article, authored by SA Transcripts, highlights the company's participation in this event. SA Transcripts is responsible for publishing thousands of quarterly earnings call transcripts and other transcript-related projects on Seeking Alpha.

AngioDynamics Port Catheter Lawsuit

https://www.wisnerbaum.com/defective-medical-device-injuries/angiodynamics-port-catheter-lawsuit/
Wisner Baum is actively investigating claims against AngioDynamics and Navilyst Medical concerning implantable port catheters due to reported complications like infection, thrombosis, device fracture, and migration. The AngioDynamics Port Catheter MDL, centralized in California, has grown to over 400 pending actions as of July 2026, with bellwether trials anticipated. The lawsuits allege design and manufacturing defects, failure to warn consumers, negligence, and breach of warranties, claiming the polyurethane catheters degrade and release barium sulfate particles, leading to serious health issues.

(ANGO) Price Dynamics and Execution-Aware Positioning

https://news.stocktradersdaily.com/news_release/23/ANGO_Price_Dynamics_and_Execution-Aware_Positioning_080826101402_1786241642.html
This article from Stock Traders Daily provides an AI-driven analysis of Angiodynamics Inc. (NASDAQ: ANGO), highlighting strong sentiment across all horizons and significant upside potential due to a lack of resistance levels. It outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for near-term, mid-term, and long-term horizons. The report emphasizes real-time signals, risk management parameters, and advanced AI models for optimizing trading decisions.

AngioDynamics, Inc. (ANGO) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/ANGO/
This article provides comprehensive financial information for AngioDynamics, Inc. (ANGO), including its current stock price, trading activity, key financial metrics, and an overview of its medical technology products. It also features performance comparisons against the S&P 500, earnings trends, analyst ratings, and a list of comparable companies in the medical instruments and supplies industry.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement